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Abstract
Introduction
Preventable adverse effects of medicines often pass unnoticed, but lead to real harm.
Intervention
Nurse-led monitoring using the structured Adverse Drug Reaction (ADRe) Profile identifies
and addresses adverse effects of mental health medicines.
Objectives
This study investigated the implementation and clinical impact of ADRe, and barriers to and
facilitators of sustained utilisation in routine practice.
Methods
Administration of ADRe was observed for 30 residents prescribed mental health medicines
in ten care homes. The study pharmacist reviewed completed ADRes against medication
records. Policy context was explored in 30 interviews with service users, nurse managers
and strategic leads in Wales.
Results
Residents were aged 60–95, and prescribed 1–17 (median 9 [interquartile range (IQR)
7–13]) medicines. ADRe identified a median of 18 [IQR 11.5–23] problems per resident and
nurses made 2 [1–2] changes to care per resident. For example: falls were reported for 9
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residents, and care was modified for 5; pain was identified in 8 residents, and alleviated for
7; all 6 residents recognised as dyspnoeic were referred to prescribers. Nurses referred 17
of 30 residents to prescribers. Pharmacists recommended review for all 30. Doubts about
administering ADRe, sometimes expressed by people who had not yet used it, diminished
as it became familiar. ADRe was needed to bridge communication between resident, nurses
and prescribers. When barriers of time, complacency, and doctors’ non-availability were
overcome, reporting with ADRe made prescribers more likely to heed nurses’ concerns
regarding residents’ welfare. Clinical gains were facilitated by one-to-one time, staff-resident
relationships, and unification of documentation.
Implications
To our knowledge, ADRe is the only instrument that brings a full account of patients’ prob-
lems to medication reviews. This juxtaposition of signs and symptoms against prescriptions
facilitates dose adjustments and de-prescribing and leads to: reduced pain and sedation;
early identification of problems linked to ADRs, such as falls; and timely medication reviews
e.g. for dyspnoea.
Introduction
Preventable adverse drug reactions and events (ADRs/ ADEs) have proved an intractable
problem over the last decade, causing 5–8% of unplanned hospital admissions in the UK [1, 2]
rising to ~10–15% amongst older adults [3–5], costing the UK NHS £1bn-£2.5bn each year
[6]. ADRs linked to avoidable errors are responsible for 712–22,303 UK deaths each year, cost-
ing £98.5 m–£1.6bn [6]. However, higher prevalence in larger prospective studies [7], and
widespread non-recognition [8] suggest that these figures may be an underestimate. Admis-
sions related to ADRs are associated with 28–32% longer hospital stays [9] and ADRs/ADEs
frequently lead to re-hospitalisation [10]. All-cause mortality is higher amongst older adults
prescribed mental health medicines [11]. Demographic change and increased prescribing are
likely to exacerbate ADR-related problems, and there is uncertainty over the best strategy for
medicines optimisation [12].
Poor medicines’ management, including errors by patients and professionals, is largely pre-
ventable [5, 13] particularly with additional enhanced monitoring [14–19]. The Adverse Drug
Reaction (ADRe) Profile [20] merged from earlier research on ADRs and nurse-led medica-
tion checking, and was designed to improve practice in this area, initially in relation to mental
health medicines prescribed for care home residents [21, 22].
The ADRe Profile represents a unique approach to collating patient information and testi-
mony to minimise ADRs, optimise prescribing, and prevent medicines-related harm and
admissions. It asks nurses or carers to record the signs and symptoms of the undesirable effects
of mental health medicines, as listed in manufacturers’ summaries of product characteristics
(SmPCs). The supporting information suggests putative aetiologies for each sign or symptom
[21]. ADRe is then shared with pharmacists and doctors reviewing medicines administration
record (MAR) charts. This paper reports on implementation and operation of ADRe in a sam-
ple of Welsh care homes.
The Adverse Drug Reaction (ADRe) Profile improvement initiative: Observations and interviews
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Aims
The aims of this study were to investigate: 1) implementation of ADRe in care homes for older
people, 2) the clinical impact of ADRe, including integration with pharmacists’ medication
reviews, and 3) the barriers to and facilitators of sustained utilisation in routine practice.
Methods
Ethical approval was conferred on 17th February 2017 from NHS (National Health Service)
Wales Research Ethics Committee (REC) 6 (reference no. 16/WA/0358, IRAS ID 213050). The
study design and methods were described in the study protocol [21] and are only summarised
here, in accordance with SQUIRE 2.0 and COREQ standards (S1 File).
Sample size
We estimated that 30 interviews and 30 observations would allow for 4–5 themes at 50% preva-
lence with 10 instances with 90% power, and would achieve data saturation[21].
Inclusion criteria
We included residents who were: expected to remain in the home for one year; currently
taking any of antipsychotics, antidepressants, anti-epileptics/ mood stabilisers, anxiolytics or
hypnotics (benzodiazepines or Z drugs); willing and able to give signed informed consent
themselves, or where capacity was lacking, having a consultee willing to give advice. We
excluded those not well enough to participate, as screened by their nurses, aged<18 or receiv-
ing active palliative care [21].
Stakeholder interviews were conducted with study participants and key stakeholders able
to give a strategic overview of the problems, including strategic leads, and the care home
inspectorate [21].
Recruitment
Volunteer care homes were sought at dissemination events and by emails sent to all 53 eligible
care homes in one Welsh health board area. After initial discussion, each care home manager
was sent detailed information. Residents were recruited by their nurses based on their pre-
scriptions [21]. Three homes that had participated in the feasibility study [23], and linked with
a participating home, were excluded. Professionals and service users interviewed were nurses,
and where possible, residents or service users from the 10 care homes, and stakeholders identi-
fied by snowball sampling (Fig 1).
Setting. Administration of ADRe was observed in ten homes caring for people prescribed
mental health medicines: five from our earlier randomised controlled trial [24], and five newly
recruited. The wider policy context was explored in 30 interviews with service users, nurse
managers and strategic leads in Wales.
Design
This mixed-method evaluation integrated data from non-participant observation, nurses’ logs
and interviews to explore how, and why ADRe works, and in what contexts [25, 26]. Debrief-
ing and stakeholder interviews explored the problems uncovered, the role of ADRe in identify-
ing them, changes needed to optimise clinical gain and communication between professionals.
The Adverse Drug Reaction (ADRe) Profile improvement initiative: Observations and interviews
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Fig 1. Participant flow diagram.
https://doi.org/10.1371/journal.pone.0220885.g001
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Outcomes
1. Implementation experiences: discrepancies between “as intended” and “as delivered”.
2. The clinical impact of ADRe was measured via a) problems found b) changes in processes
and outcomes of care: additional care delivered, as indicated by nurses, and number and
nature of clinical gains, and c) the potential for ADRe to enhance pharmacists’ medication
reviews. All signs and symptoms were recorded to avoid outcome selection bias.
3. The barriers to, and facilitators of utilisation in routine practice were investigated using
both observation and interview data. Contextual elements contributing to clinical gain were
noted.
Data collection
Between September 2017 and March 2018, researchers observed administration of ADRe to 30
residents in 10 care homes (SJ, MGW, SS, MS, GP) and interviewed 30 stakeholders (SJ, MGW,
DH, JM, SS, MS). Data collection templates and interview questions were based on earlier work
[24] and a pilot feasibility study [23] and finalised at project meetings (Tables A1 and A2 in S3
File, S2 File). Free-text fieldnotes were recorded. Interviewers were researchers with extensive
experience of qualitative interviewing, with one exception, who observed earlier interviews.
Observations. We observed nurses’ implementation of the ADRe Profile with 30 resi-
dents, alongside standard care, within existing resources, and checked for evidence of adverse
drug reactions (listed in the BNF and manufacturers’ literature). The study consultant pharma-
cist (TB) later reviewed the ADRe profiles alongside a copy of the corresponding MAR charts.
Interviews. Thirty semi-structured qualitative interviews were conducted with the main
stakeholders involved in the administration of medicines in care homes: nurses and care home
staff from the 10 homes (12), residents and relatives (5), prescribers (3), dispensing pharma-
cists (3), independent service users (3), strategic leads: Welsh policy makers (3) and a senior
official from the overseeing inspectorate (1). Pharmacists and prescribers were recruited via
PRIME centre Wales. Policy makers were recruited from the Welsh Government Health and
Social Services Department. Respondents opted to be interviewed in their workplaces, homes
or cafe´s. Interviews were audio-taped, transcribed verbatim and anonymised [27]. The inter-
view schedule is appended (S2 File).
Analysis
Demographic details, time for implementation, instances of problems identified on ADRe Pro-
files, and numbers and reasons for referrals were described using measures of central tendency
for both normally and non-normally distributed data to facilitate consistency in reporting.
Interviews and observation fieldwork were coded, categorised, analysed and closely interpreted
by all authors [21]. Compliance and clinical gains were described. Interview analysis was based
on the constant comparative method [28]. The two data sets were triangulated to identify com-
mon themes as described in the published protocol [21] (Fig 1). The previous themes of clinical
gains, barriers, facilitators and proposals for change formed a provisional template [20–24].
Final codes and themes, as well as data saturation, reflected collective decisions.
Ethics
The local NHS Research Ethics Committee approved the study on 17th February 2017. Written
and verbal information was offered and potential participants. Written informed consent was
The Adverse Drug Reaction (ADRe) Profile improvement initiative: Observations and interviews
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obtained for all interviews and observations. Where nurses judged that residents lacked capac-
ity to consent, consultees signed on their behalf; consultees were relatives or professionals not
involved in the study, who were in regular contact with the participants [21].
Results
Recruitment and retention
The research design involved data collection in ten care homes, comprising five from the pre-
vious trial [24] (100% retention) and the first five of seven ‘new’ care homes to respond posi-
tively to our invitation to 50 eligible care homes (14% response rate) (Fig 1). However, three
of these latter five subsequently withdrew. These were replaced with two who had volunteered
after we reached our target, plus a home approached on our behalf by a participating manager.
Of the three withdrawals, one home closed, and two reported that staff found ADRe too ‘diffi-
cult’. This prompted us to interview independent service users [3].
Nurses were interviewed from all ten homes, and eight nurses returned logs of patient
responses. Residents were difficult to recruit to interviews because relatively few were capable
of participating, and resident or family interviews were only completed in five homes (six
in all). In nine homes, all residents initially approached by their nurses consented to being
observed; in the tenth, one resident declined and was replaced by an additional resident from
another home. In all homes, we witnessed only care, kindness and compassion. The 30 resi-
dents observed are described in Table 1.
1. Implementing ADRe
ADRe administration took 10–50 minutes (Table 2). Nine administrations were interrupted
and distractions occurred in a further five, extending the time needed for completion. Record-
ing vital signs took ~7 minutes. Equipment was missing for 20 observations, increasing time
taken as working sphygmomanometers or thermometers were sought, sometimes in vain. Two
sphygmomanometers failed to give readings from a standing position, and one nurse using
previous BP recordings found only sitting BPs recorded. Given the associations between men-
tal health medicines and hypotension, omissions of vital signs detracted from assessments of
ADRs, and clinical impact. No laboratory or ECG results were available in homes (Table 3a
and 3b); typically, results were logged in GPs’ surgeries. This was concerning for a man pre-
scribed cyproterone (8.2) and more so for a woman prescribed lithium (9.1, age 93), as several
problems identified might have been related to lithium (tremor, confusion, ataxia, falls and
xerostomia), and perindopril, quetiapine and venlafaxine were co-prescribed.
Table 1. Demographic details of the residents observed n = 30.
Mean [SD] Median [IQR 25th to 75th centile] Range (min-max)
Age (years) 77.7 [9.9] 78 [69–85.25] 60–95
Time nurse had known resident (years) 3.8 [5.0] 2.0 [0.5–5.0] 0.25–24
Number of medicines prescribed 9.6 [4.1] 9 [7–13] 1–17
n (%)
Male 15 (50)
At start of study receiving:
• Residential care 19 (63%)
• Nursing care 11 (37%)
SD standard deviation, IQR interquartile range
https://doi.org/10.1371/journal.pone.0220885.t001
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While most questions were completed in the order on ADRe, vital signs were sometimes
postponed. Where these had been recorded in the resident’s notes within the last week, they
were often transferred; where vital signs were stable, this was considered acceptable by care
staff. Some residents had limited comprehension and speech, and entries were sometimes
based on nurses’ interpretations of their health and records, for example, of bowel movements.
2. Clinical impact
a) Problems found. Care staff identified around 17 potential problems per resident when
completing ADRe (Table 2), ranging from the need for oral care to extrapyramidal signs to
chest pain and oxygen saturation of 89% (Tables A1 and A2 in S3 File). They made around
two changes to care per resident, with changes recorded for 27 of 30 residents. In 17 cases pre-
scribers were contacted, mainly for ‘medication review’ to address problems identified, but
usually with a specific focus, such as reducing specified mental health medicines, suspected
UTI or respiratory problems. Signs and symptoms possibly related to mental health medicines
were almost universal. Nearly all residents had been reviewed by dentists (23 of 30) and opti-
cians (29 of 30) in the last year. Problems found and addressed are listed in Tables A1 and A2
in S3 File.
Possible iatrogenic aetiologies of the problems recorded on ADRe were identified by the
study pharmacist and checked (Tables 2 and 3). These included up to eight medicines predis-
posing to falls, seizures likely exacerbated by drug interactions or irregular administration of
medicines, diarrhoea where laxatives had been prescribed (for earlier constipation), insomnia
where olanzapine was administered too early, at 6.00pm, under-treatment of respiratory con-
ditions, and pruritus due to suboptimal application of prescribed emollients. Continuation of
some therapies was queried, for example, statins, bisphosphonates in non-ambulant residents,
and medicines for prostatic hypertrophy with catheters in situ. Alcohol use was identified in
two residents, possibly accounting for behaviour problems that might otherwise have been
attributed to carbamazepine (home 2.1).
b) Processes and outcomes of care. Not all problems identified on ADRe were addressed
(Tables A1 and A2 in S3 File), and some were not amenable to medical intervention. Debility,
insomnia, cognitive decline and confusion were related to underlying disease, but were often
exacerbated by prescribed medicines. Clinical gains ranged from effective analgesia to amelio-
ration of sedation, confusion or hallucinations on discontinuation of antipsychotics (described
in Table 4). In six of eight logs returned, nurses reported contacting prescribers to seek reduc-
tion in doses of antipsychotics or sedatives. Residents were reported to be ‘brighter’ where the
prescriber acquiesced (five homes).
Some homes adopted ADRe more enthusiastically than others. Implementation appeared
most successful where benefits were recognised (despite initial scepticism in some instances)
and prescribers responded to contacts. Certain barriers to introduction of ADRe were evident
Table 2. Summary of outcomes for residents (n = 30).
Observation Mean [SD] Median [IQR 25th to 75th centile] Range (min-max)
Time for ADRe administration, including interruptions (minutes) 27.7 [12] 28.5 [18.75–40.00] 10–50
Number of problems identified / resident 17.5 [7.1] 18 [11.5–23] 6–32
Number of changes to care by nurses / resident 2.3 [1.6] 2 [1–2] 0–6
Number of pharmacist recommendations for prescription review / resident 3.8 [2.1] 3 [2–5] 1–10
Number of drug interactions� / resident 6.1 [5.7] 6 [1–9] 0–22
�using BNF drug interaction checker
https://doi.org/10.1371/journal.pone.0220885.t002
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Table 3. Potential gains identified by pharmacist review: Examples only, not a complete list.
Home Problems on ADRe Possible iatrogenic aetiologies Comments, including pertinent data
1. Dyspnoea Asthma under-treated (beclometasone 200mcg bd, Ventolin
200mcgs inhaled qds)
Oxygen saturation was key to problem recognition.
Postural hypotension Quetiapine, venlafaxine, solifenacin, amlodipine, Falls risk. ADRe informed the pharmacist that the patient had a catheter
in situ.
Weight gain Mirtazapine [29]
Oedema Amlodipine
2. Aggression Carbamazepine, aggression exacerbated by alcohol.
Indigestion + constipation Adcal D3 (contain calcium) tablets administered for
indigestion.
SmPC lists these as ADRs
Risk of falls: poor gait, confusion Ramipril, zopiclone, carbamazepine BP not recorded. Seizures, but no falls reported.
Convulsions, insomnia, irritability,
eczema
Levetiracetam ADRe indicated that seizures were recurring, and only 1 AED had been
prescribed.
Feeling cold, lethargy, insomnia Propranolol Carers were not aware that the resident felt cold. Propranolol had been
prescribed for years, but this was the first request for a review.
Seizures Dose of valproate low, no other anticonvulsants prescribed. Only record of seizures was on ADRe.
Aggression, confusion Valproate
Diarrhoea, incontinence Magnesium, valproate The association between diarrhoea and magnesium had not been
recognised.
3. Falls Bendroflumethiazide, ramipril, tamsulosin, zopiclone,
haloperidol
Falls risk re-assessed by nurses. Postural hypotension noted for first
time on ADRe.
Resident non-ambulant Are risendronate, calcium and folate still needed? GP prescribing not reviewed by mental health team.
No constipation Senna, magnesium (2 of 3 residents)
Falls risk: balance/ gait / shuffling /
restlessness
Ramipril, risperidone, lorazepam, diazepam, carbamazepine,
furosemide
Prolonged QTc risk noted by pharmacist.
balance/ gait / shuffling / restlessness Risperidone Prescriber contacted, risperidone discontinued.
4. Shuffling, restlessness Risperidone (2 of 3 residents) Reviewed and discontinued.
Postural hypotension, falls risk Risperidone, timolol eye drops The only documentation of standing BP was on ADRe.
Glaucoma Sertraline + antipsychotic
Weight gain Valproate
Aggression Oxazepam, valproate Aggression was problematic for staff
Falls Oxazepam, valproate, zopiclone, olanzapine
Daytime sleeping + insomnia Olanzapine given too early (6.00 pm.)
Falls (ataxia, poor gait) Ramipril, bisoprolol, risperidone, lorazepam, carbamazepine,
PRN temazepam
Sedatives reviewed and reduced.
Insomnia Risperidone given at night Morning administration is advised.
Tongue movements, shuffling, gait
abnormal
Risperidone Not previously recorded in notes.
5. Chest pain (possibly cardiac) Salbutamol nebules bd. + inhaler qds, chlorphenamine (above
recommended dose), furosemide, prednisolone
Medicines review requested by nurse. (Digoxin co-prescribed and no
potassium results located.)
Dyspnoea Morphine + co-codamol Referral to respiratory nurse advised.
Insomnia Temazepam, Oramorph1, chlorphenamine, promazine given
in the evening
Pharmacist advised discontinuation of all hypnotics and review of sleep
hygiene.
Pain at night Under-treatment Nurse to request longer-lasting analgesia e.g. transdermal preparation
Day-time sedation Co-codamol, chlorphenamine, morphine, temazepam PRN Pharmacist advised discontinuation of all hypnotics and review of sleep
hygiene.
Pruritus Emollient creams not administered, furosemide
Oedema Prednisolone
Tremor Promazine, salbutamol
Feeling cold Bisoprolol
Convulsions, black outs, headaches Citalopram antagonises phenytoin. Citalopram + paracetamol
+ metoclopramide risks CNS toxicity
Metoclopramide appears to be long-term (indicated for 5 days only).
Falls, postural hypotension Citalopram, phenytoin ADRe offered the only documentation of standing BP.
Mood fluctuations Beclometasone, salbutamol
Hypotensive (chair bound), hypoxic Diazepam, nitrates, sertraline, morphine
(Continued)
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(Table 4). Triangulation of cases and nurse feedback via in-depth interviews validated these
themes (Table 5; Table B in S3 File).
Vital signs. ADRe introduced recording of oxygen saturation, standing BP, and girth. Hyp-
oxia was recognised as a problem in three of nine residents with hypoxia (Table 4, homes 1,5);
otherwise symptoms were attributed to asthma or former smoking or marked as “no problem”.
Thirteen residents were assessed for possible postural hypotension: two had a SBP fall of
�20mmHg, and two of�10mmHg (3 of the 4 were prescribed antipsychotics, three antide-
pressants and two both). Nurses noted the need to recheck, assess risk of falls or advise resi-
dents to stand slowly. ADRe identified mental health medicines, anti-hypertensives, medicines
for prostatic enlargement, and drug combinations as potential aetiologies and advised on falls
(Table A1 in S3 File, Tables 3 and 4, homes 1 & 7).
Falls. ADRe recorded falls for nine of 30 residents (6 of whom were prescribed antipsychot-
ics), ataxia for 14 (nine prescribed antipsychotics), dizziness for seven (five prescribed antipsy-
chotics), and postural hypotension for four (above). Nurses amended care plans for five
Table 3. (Continued)
Home Problems on ADRe Possible iatrogenic aetiologies Comments, including pertinent data
6. Dyspnoea / hypoxia Possible under-treatment of COPD (ipratropium 500mcg qds,
salbutamol 100mcgs qds), benzodiazepines
Prescriber contacted
Constipation Iron, salbutamol, ipratropium Iron dose and formulation adjusted
Loose teeth, dry mouth Ipratropium
Bowel control Lactulose
Lethargy Atorvastatin Statins of questionable overall value in people aged >80+ [30]
Seizures Carbamazepine monotherapy administered at different times
each day.
Nurses previously unaware of the problems with this practice.
7. Tremor Valproate, levetiracetam, phenytoin Known severe epilepsy.
Seizures Valproate and phenytoin
Hypotensive, tachycardia, hypoxic,
unable to stand
Amlodipine, baclofen, oxycodone, doxazosin, furosemide,
losartan, fluoxetine.
BP and oxygen saturation not routinely monitored. Pharmacist
requested this.
No response to intake questions.
8. Falls / dizziness, abnormal movements /
ataxia
Mirtazepine, memantine, tamsulosin (BP drop), diazepam,
venlafaxine, quetiapine
Quetiapine not recommended for people with dementia.
Mood problems Mirtazapine, simvastatin, lansoprazole
Tongue movements/ abnormal
movements / tremors / shuffling / ataxia
Zuclopenthixol, valproate, lorazepam Not previously recorded in notes
Double incontinence Senna, magnesium, iron
Falls / dizziness / gait abnormal Risperidone, atenolol, citalopram, saxagliptin, zopiclone,
diazepam, memantine and atorvastatin
Recommendations to withdraw mental health medicines. Prolonged
QTc risk noted by pharmacist.
Hallucinations (aggression and violence) Citalopram, zopiclone, memantine, possibly amlodipine Aggression was a problem for the staff.
9. Falls / tremor / ataxia / dizziness Quetiapine, lithium, venlafaxine, alprazolam,
perindopril, amlodipine
BP records not available.
Prolonged QTc risk noted.
Confusion / headache Quetiapine, lithium, venlafaxine, alprazolam, perindopril,
amlodipine, lansoprazole
Complex regimen needed considerable prescriber input.
Insomnia + daytime sedation Risperidone administered nocte, diazepam mane, zopiclone Timing of administration to be reviewed.
10. Ataxia / falls risk / confusion Olanzapine, amlodipine, ramipril, co-dydramol, valproate,
wine every night
Hypoxia (92%) Under-treatment of COPD (no medicines listed) Review sought.
Ataxia, shuffling, restlessness Risperidone Discontinued.
Note to Table 3:
ADRe provided reassurance that some drug interactions had not adversely affected the patient:
• No convulsions despite possible antagonism between up to 3 AEDs and antipsychotics (1.3, 4.2, 4.3)
• No signs of bleeding despite several anti-coagulant / antiplatelet agents (1.1). However, major bleeds can occur without prodromal blood loss.
• Not hypotensive despite several antihypertensives (8.3).
https://doi.org/10.1371/journal.pone.0220885.t003
The Adverse Drug Reaction (ADRe) Profile improvement initiative: Observations and interviews
PLOS ONE | https://doi.org/10.1371/journal.pone.0220885 September 11, 2019 9 / 27
Table 4. Clinical gains: How ADRe helped—Facilitators and barriers (examples).
Home Clinical gains: how problems found on ADRe were
addressed
Facilitators / gains at home level Barriers
1. • Dyspnoeic, hypoxic resident was referred to GP for
management of respiratory condition
• Hypertension, subsequently corrected (2 residents)
• Diarrhoea corrected by reduction of laxatives
• Falls risks detected and monitored.
• Dizziness and falls linked with antipsychotic—review
sought
• Hyper-salivation addressed by hyoscine patch.
• Follow up monitoring identified diabetes, which was
treated.
• Increased monitoring: postural hypotension and oxygen
saturation to be monitored as on ADRe.
• Profiles placed in residents’ files.
• Profiles to be completed monthly and mental health
team engaged.
• Increased nurses’ awareness of side effects.
• Risk of duplication, as some monitoring is
already done.
2. • Urination problems identified led to UTI recognition
and report to GP
• Worsening convulsions reported to GP.
• Balance poor—to be observed.
• Resident reported feeling cold. Extra blankets made
available at night.
• All information in 1 place allows nurse to focus on the
person.
• Identification of alcohol consumption helped
pharmacists review drug interactions.
• Profile helps to “think things through”, improves
knowledge and awareness.
• Resident positive about ADRe and reacted unusually
well to researcher.
• Highlighted need for vital signs, not currently
documented, and medicines reviews.
• Nurses unsure how ADRe fits with other
documentation. Care plans simply entitled
“physical and mental health”.
• Some problems e.g. seizures, challenging
behaviour, are already documented, but
without indication of medication reviews.
• Difficult, unresponsive, hung-over and
unpopular patients.
• Vital signs not recorded.
3. • Regular antipsychotic administration discontinued
throughout the home. PRN prescriptions available.
• Mood settled, felt safe at night, slept at ease when
antipsychotics discontinued. Hallucinations improved
since haloperidol reduced, and then stopped.
• Pain: analgesia reviewed
• Insomnia reduced when risperidone given mane
throughout the home.
• Weight loss addressed by diet diary monitoring and
finger feeding.
• Juxtaposition of weight gain, feeling cold and hair
loss prompted testing for hypothyroidism, which was
then corrected.
• Passing information on gait, shuffling and balance to the
prescriber led to reduction and discontinuation of
antipsychotics.
• “Using the profile has enabled us to identify and monitor
problems associated with the use of antipsychotics. Staff
are able to produce documented evidence to multi-
disciplinary teams, to make recommendations to
improve residents’ wellbeing. Staff feel valued;
improvement in self-esteem has been noted. Overall
benefits of using the profile has been significantly
reduced, and, in some cases, discontinued,
antipsychotics. Staff have become more aware of adverse
drug reactions associated with these drugs, which has
improved the quality of physical health for residents,
preventing unnecessary admissions to hospitals.”N3
• Resident said the research “is a good thing”.
• Mental health team engaged and reviewing profiles.
None identified.
4. • Reduction of antipsychotics throughout the home.
Nurse liaised with mental health team.
• Tremor and hypersalivation alleviated by reduction
of antipsychotics.
• “Much more settled” when risperidone discontinued.
• Sedation, benzodiazepines reduced to PRN (x2),
noted as “not required”.
• Insomnia: zopiclone discontinued as ineffective.
• Urine checked, fluids encouraged throughout the
home.
• Mental health team responsive.
• Profile identified and drew attention to tremor, swelling,
cognitive decline.
• Residents liked the attention, welcomed the checks and
felt reassured.
• Residents and families were pleased the nurse was taking
the time to check.
• Profile a bit long
• Problems already in care plans e.g. falls, but
not linked with medicines
• Care plans not shared with prescribers
routinely.
5. • Pain: analgesia arranged (x3)
• Dyspnoea, GP contacted to review and ensure
nebuliser available if needed.
• Vision poor, optician contacted.
• Urine tested.
• Residents have the opportunity to document requests to
see GP, and offer him a list of problems. Accordingly,
GP contacted to review medications of all residents
• Nurse wishes she had been more assertive with GP.
• The project identified the need to check when drugs are
started.
• Residents described ADRe as “a very good thing”.
• GP not reviewing medicines when contacted.
• Some clients unable to understand the
questions
• Clients’ disabilities limit their progress
• Clients with learning disabilities and hearing
difficulties cannot discuss meds. Client
repeatedly dismantles hearing aid.
(Continued)
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residents in relation to dizziness, ataxia, postural hypotension or falls (Table 4, homes 1,7),
without mentioning any relationship to medicines. The pharmacist recommended medication
review to address risks of falling due to factors such as ataxia, dizziness or extra-pyramidal
symptoms (EPS) for 14 residents, attributable to antipsychotics (8), AEDs (5), antidepressants
(6) anti-hypertensives (3), benzodiazepines or zopiclone (6), and combinations of medicines.
Ten of these 14 residents were referred to prescribers by their nurses (Table 4).
Table 4. (Continued)
Home Clinical gains: how problems found on ADRe were
addressed
Facilitators / gains at home level Barriers
6. • Falls, agitation, slurred speech triggered GP home
visit, and medicines were reduced.
• Constipation improved when oral iron reduced, and
fluid and fruit intake increased. A laxative was
requested. Swallowing difficulties and ‘lacks energy’
prompted request for transfer to liquid iron
preparation.
• Swollen, hot, dry, itching legs prompted skin care.
• Sleeping problems identified for a hypoxic resident
using CPAP (continuous positive airways pressure)
• By identifying unrecognised problems, ADRe initiated
GP referral for all residents.
• Structured baseline information ready for GP visit.
• Nurses decided medicines needed changing as the best
way to address problems e.g. falls, agitation, slurred
speech.
• Residents liked the attention.
None identified.
7. • Falls—risk assessment undertaken
• Hypotensive and hypoxic resident administered
amlodipine (presumably for hypertension),
furosemide 40mg, losartan, and an alpha blocker.
Pharmacist requested repeat vital signs and review of
17 medicines with 16 potential interactions. GP
review sought.
None identified by nurses. • Medicines review by GP requested, but nurse
fears GP only responds to changes.
• Medicines not routinely reviewed.
8. • Pain—analgesia administered.
• Over-weight (105.5 kg). Diet diaries completed and
referred to dietician. (Note, hoists and other
equipment sometimes have weight restrictions.)
• Restless, aggressive, violent, confused, hallucinating,
behaviour problems: GP medicines review sought
and 2 medicines discontinued.
• “ADRe helps nurses’ understanding of health conditions,
medicines and their changes. It addresses training issues.
(. . .)
• Good opportunity to get to know and understand
someone, particularly if you are new to nursing.”N8
• Families would like medication reviews.
• Too many problems: “Decided not to write
problems in care plan, as it would take a long
time.”
• Problems accepted as “normal for the
resident”.
• “People don’t have time to review”.
• “They won’t touch complex patients” (13–15
medicines per resident in this home).
• Psychiatrist unavailable SU8
• Breaking tablets–doses received may be
unpredictable.
9. • Knee pain identified and resolved by paracetamol
administration.
• Weight loss after hospitalisation monitored by diet
diary.
• Weight gain, sugar and snacking reviewed with diet
diary.
• “Made me feel good that I helped the resident who was
in pain. (. . .)
• Gives quality time with residents, confidence, and
thinking.” N9
• BP only taken by district nurses when they
call.
• No vital signs recordings available.
10. • Confusion, sedation, sleep interfering with intake,
cognitive decline. Nurse contacted prescribers and
pharmacists. Subsequently, antipsychotics reduced to
PRN for all residents, and 3 participants no longer
taking any mental health medicines. Residents noted
as less drowsy.
• Confusion and sedation—GP referral, diazepam and
zopiclone discontinued and problems ameliorated.
• Aggression ceased when promazine stopped.
Activities introduced for challenging behaviours.
• Incontinence ceased when promazine stopped.
• Intake poor (due to sedation), missing meals. Mid
arm circumference and diet diary monitored to
optimise intake.
• “We can look immediately at mental health medications
which may be causing confusion and drowsiness. (. . .)
• ADRe identified the Epilim dose was adding to Mrs. H’s
confusion; she has no seizures, and is less confused.
• Identified that Mr.D did not require diazepam; now
more alert & occasionally speaks. (. . .)
• Identified that Mr. R’s behaviour was the same without
the promazine.”N10
• Vital signs recorded on other documentation
in the home. These need to be transcribed or
ADRe needs to be integrated with other
documentation.
https://doi.org/10.1371/journal.pone.0220885.t004
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Table 5. Clinical gains, barriers and facilitators: Triangulation of observations, profiles and interviews with case examples. Full details with prescriptions in Table B
in S3 File.
Theme Subtheme Participant Case reports Extracts from Interviews
Clinical
gains
Patient more contented
following reduction of
antipsychotics.
3.2
Woman, 84
When ADRe was shared with the consultant, haloperidol
was reduced, then stopped. PRN was retained, but rarely
used. Mood settled, and 3.2 said she felt safe at night, and
slept at ease. Underactive thyroid identified and treated.
“We look at the daily logs and the profile when we do
their monthly care plans to see if we can find a reason.
(. . .) So when the consultant team come, we can present
the case. Obviously, the doctors are only coming and
seeing the clients for a very short time, 1 afternoon
every 10–12 weeks, so we give them as much
information as we can, especially when we are saying to
them, look, we don’t think this resident requires this
amount of haloperidol. If we have got the evidence, they
are much more inclined to take our word for it, listen to
our point of view.” N3
Aggression and incontinence
disappeared when
antipsychotic discontinued.
10.2
Man, 95
Nurse completed ADRe, and used it as evidence to
persuade GP to discontinue antipsychotic. Promazine was
stopped, and within a month aggression and
incontinence were no longer problems.
“[He was] much brighter. He was quite drowsy when he
was on the medication. But once we’d convinced the
doctor, that he really didn’t need it and we could
manage his behaviour, he was actually all right & he
settled, there was no problem, so he didn’t need the
medication after all.” N10
Barriers Time as a problem for nurses
and doctors
2.2
Woman, 63
The only records of seizures were on ADRe. ADRe
documented that seizures were occurring, and was used
to report to prescribers. Researchers noted levetiracetam
might be contributing to seizures as well as insomnia,
eczema, irritability. However, no changes were made.
Vital signs not recorded, and lack of time was given as
the reason.
Despite lack of time, convulsions were reported to
prescribers
“There is no possible practical way that one is going to
get to see senior medical staff and prescribers: it’s just
not going to happen. The psychiatrist relies very heavily
on what the care staff are saying. This might strengthen
what the care staff are able to say about medicines
impact, and we can only react positively.” SU2 (family)
Confirmed by nurses:
“You’ve got to produce the evidence to the GP and this
is ideal to produce the evidence.” N2
“I don’t think GPs have got the time. They do their best
while they are there, but it’s not routine to check on
every patient regularly.” SU8 (family)
Fit with other documentation
/ resistance to change
1.1
Man, 66
Vital signs results and ADRe were passed to GP with a
referral for full medication review (over a year since last
review) to address hypoxia, hypotension, dyspnoea,
absence of constipation (laxative prescribed).
The home enhanced their monitoring.
“We do monthly observations regularly, and as and
when. So it’s like duplicating what we already do, but it
is more in-depth. (. . .) it has highlighted some of the
things that you wouldn’t think about asking, like dry
mouth, gait, the physical side effects. (. . .) there are
some things that I would never have thought to look for
—tongue movements.” N1
“. . . Integrating this [ADRe] into routines, looking at
whatever else they are monitoring with a view to
keeping it manageable and not distracting them from
interaction with residents.” Su2
Prescribers 5.1
Woman, 83
ADRe identified chest pain, dyspnoea and insomnia.
However, there was no response from the GP.
The pharmacist indicated that sleep would be improved
by moving promazine to morning administration,
reducing doses of chlorphenamine to within BNF
guidelines (from 16 to 12mg/ day), discontinuing
ineffective hypnotics and reviewing salbutamol nebules
and inhalers as indication was not clear.
An optician’s appointment was made.
“What I found here is that the GPs are not very
forthcoming. Um, it’s like today, the phone call that I
got from the doctor with reference this lady, I had to
make a week ago, so to me that’s not good enough,
really. You’ve got to book a telephone consultation, if
you want to discuss someone’s medications or to get
advice on medication. You speak to the receptionist that
you want to speak with the GP with reference bla, bla,
bla, you could be waiting two—three days. Then you get
frustrated yourself really. (. . .) ADRe picked up 2 issues.
Like I say, I spoke to the GP, they weren’t forthcoming
in helping, but they shut me down, really.” N5
The resident corroborated the nurse’s request for
additional input: “The tablets I’m taking, I don’t know
what they are for. Bed time tablets, I take them between
9 and 10, I go to bed and I’m awake between 1 & 2. I’m
taking sleeping tablets & I can’t sleep & Oromorph–I’m
still not sleeping.” SU5.1
(Continued)
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Weight. Action regarding weight change was taken for 11 residents, and for current weight
for a further two, including introduction of diet diaries for nine (Table 4, homes 3,9). The
pharmacist suggested that mirtazapine and valproate might be associated with weight gain, but
this was not actioned.
Table 5. (Continued)
Theme Subtheme Participant Case reports Extracts from Interviews
Nurse complacency /
entrapment by prior
expectation
7.2
Woman, 62
ADRe recorded oxygen saturation 94%, BP 109/75, HR
104, posture abnormal, dry eyes, unable to stand. 7.2 was
hypotensive and taking amlodipine (presumably for
hypertension), furosemide 40mg, losartan, baclofen,
oxycodone, doxazosin. Tachycardia indicated
baroreceptor reflex activated & hypoxia suggested
reduced tissue perfusion, possibly linked with
hypotension.
“Unlikely the medicines will be changed. I am sure they
won’t be changed.” N7
“We get used to that person, so we might omit some
signs that we don’t actually think are noticeable (. . .) the
profile will ask you different questions that maybe you
never thought of. (. . .) you might see but might classify
that as age. You might not actually put it down to
medication.” N6
Overwhelmed by the system /
defeatism
5.3
Woman, 81
ADRe identified pain for the first time, and the nurse
reported to GP, seeking stronger analgesia and a
medication review. However, there was no response.
“To me personally, it feels like they’re old, they’re stuck
in a care home, what more can they do. That’s how it
comes across to me. They put them in a care home &
forget about them. (. . .) The majority of the residents
have been here now a few years and it’s quite difficult to
start messing around with their medication.”N5
“A lot of people are on a lot of drugs that aren’t
reviewed.” I1
Staff turnover / education 2.3
Woman, 69
The pharmacist recognised that beta blockers were
causing the resident to feel cold. The nurse provided
extra blankets, but did not raise this with prescribers.
Magnesium hydroxide was prescribed to a resident with
diarrhoea.
These problems could be addressed by using ADRe’s
supporting information to educate nurses or carers.
“If you’ve got a whole shift system of quite considerable
numbers of staff dropping and changing like this, it’s
about the practical dangers of not being done
consistently. (. . .) who carries the responsibility for
making sure this is happening and making
observations.” SU2 offers to complete ADRe: “I
wouldn’t find it burdensome.”
Facilitators 1 to 1 time 9.2 woman,
69
Knee pain identified, which responded to paracetamol
administration. [9.2 was diagnosed with psychosis &
recurrent depression.]
“One of the residents we spoke to, she has pain in the R
knee. She never told anybody, when we do medication,
she never mentioned that before. We can use our home
remedy, paracetamol.” N9
Interpersonal relationships 4.1
Woman, 82
4.1 was pleased that nurses were taking time to check,
felt reassured, and enjoyed the attention.
Medication review was arranged.
Postural hypotension and falls risk were recognised, and
marked for monthly review (risperidone, timolol,
sertraline).
“We are told about what’s going on. We visit regularly
(. . .) we can always talk to staff. They [care staff] check
regularly, but if that can be improved then this is good.”
SU4 (family)
All information in 1 place 10.3
Man, 78
Nurse liaised with doctor to reduce and de-prescribe
diazepam. This removed over-sedation & confusion.
“Without using the profile, we tend to find GPs would
prescribe mental health medications that weren’t really
appropriate. ADRe identified you didn’t really need
these on a regular basis: PRN or not at all. So for all of
us at H10, it did identify that we needed to be more in
contact with the GPs & say, look you know, this isn’t
working. This person doesn’t need to be on risperidone
etc. You can distract residents: they’re much more
settled without risperidone. That’s what we found.” N10
Identifying unrecognised
problems
8.1 Man, 89 Pain was recognised and treated with paracetamol. Diet
diaries were completed to assist weight gain
management. Carer felt ADRe identified too many
problems to write them all into the care plan, but found
ADRe a good opportunity to get to know the resident.
The pharmacist identified a number of possible causes
for 8.1’s tremor and falls: mirtazapine, memantine,
tamsulosin, diazepam, venlafaxine, quetiapine.
“We get used to the person. We might omit some signs
that actually we don’t think are noticeable. . . need to
take notice when you look over the profile it will ask
you different questions that maybe you never thought
of. Someone being on a different kind of tablet might
give them tremor. You might see that but might classify
that as age. You might not actually put it as medication.
So this is why the profile is good. And maybe
sometimes we need to remember the basics of nursing.
Some of us have been doing it for so long. . .either we
forget or we make mistakes. (. . .) Then what’s actually
what’s more obvious than what’s in our face what’s in
front of us?” N8
https://doi.org/10.1371/journal.pone.0220885.t005
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Pain. ADRe identified pain for eight residents, one worsening: seven via the “pain ques-
tion” and one when checking for non-verbal cues. Nurses acted on seven reports, by adminis-
tering analgesia, monitoring pain and seeking medical advice (Table 4, homes 3,5,8,9). One
resident’s message to prescriber was “pain”.
Dyspnoea. ADRe identified six residents as short of breath, four of whom were prescribed
respiratory medicines. The pharmacist recommended review for three of four residents treated
for respiratory conditions: two had oxygen saturations�96%. Nurses referred all six partici-
pants to prescribers after administering ADRe (Tables A1 and A2 in S3 File, homes 1,4,5,6).
Feeling cold. 14 residents either said they were cold or were cold to the touch (some could
not speak). Extra blankets or clothes were offered. For two residents, the pharmacist recom-
mended review of beta blockers, but nurses had not made this connection.
Extra-pyramidal symptoms (EPS). ADRe identified problems associated with EPS: 15
instances of restlessness (11 prescribed antipsychotics), 12 of feet shuffling (eight prescribed
antipsychotics), nine of abnormal posture (seven prescribed antipsychotics), eight of abnormal
gait (six prescribed antipsychotics), five of abnormal tongue movements (all prescribed anti-
psychotics). Nurses rarely acted on hand tremor (one of nine was referred to the CMHT), and
there were no documented responses to tongue movements, abnormal posture or gait. Phar-
macist review cited EPS as a reason to review doses of antipsychotics for nine residents, AEDs
for another, and drug combinations for another.
c) Pharmacist reviews. By juxtaposing the problems listed on ADRe with the prescrip-
tions issued, around three items per resident were identified for prescription review or addi-
tional monitoring. Examples appear in Tables 4 and 5. Reviews were recommended for most
mental health medicines (Table 6), for example antipsychotic review was recommended for 17
of 18 residents. Potential problems included safety concerns e.g. falls or risk of falls due to
ataxia, abnormal gait or EPS (8), and quality of life issues e.g. insomnia when risperidone was
administered nocte rather than mane (3). Nurses referred eight of the 18, and four regimens
(all from 1 home) had been changed on initial use of ADRe, before its observed use. AED
review was recommended for 11 of 13 residents, to prevent falls (5), or address residents’ con-
cerns e.g. incontinence (1): nurses had referred six. ADRe identified both worsening (resident
Table 6. Pharmacist referrals.
Number of
residents
Antipsychotics AEDs Antidepressants Benzodiazepines or Z drugs
Prescribed 18 13 10 14
Nurses referred 8 /18 6 /13 4 /10 5 /14
Pharmacist
referred
17 /18 11 /13 8 /10 11 /14
Reasons cited by
pharmacist
Weight gain (1), falls/ balance/
gait/ EPS (8), anxiety/ sedation/
confusion (3), insomnia (3),
outdated medication (promazine)
(1)
Weight gain (1), falls/ ataxia/
dizziness (5), EPS, including tremor
(4), aggression, irritability or
agitation (6), sedation (1),
confusion (1), incontinence (1)
Falls or dizziness (6), eyesight (1),
antagonism of AEDs (2), headache and
hallucinations (1), exacerbation of
tremor, EPS, CNS depression (3)
Antidepressants increasing risks of
bleeding and prolonged QTc intervals
(2)
Falls or ataxia (6), sedation
or confusion (2),
incontinence (1), EPS (3),
aggression (3)
Also referred for
antipsychotics
- 5 /13 6 /10 9 /14
Not referred for
other mental health
medicines
3 /18 5 /13 1 /10 2 /14
Note: some residents were referred for >1 reason.
https://doi.org/10.1371/journal.pone.0220885.t006
The Adverse Drug Reaction (ADRe) Profile improvement initiative: Observations and interviews
PLOS ONE | https://doi.org/10.1371/journal.pone.0220885 September 11, 2019 14 / 27
6.3) and breakthrough seizures (resident 2.1). Most residents prescribed antidepressants were
recommended for review, sometimes to mitigate ADRs from other medicines e.g. tremor, EPS,
CNS depression (3) or reduce risks of bleeding and prolonged QTc intervals (2). Benzodiaze-
pines were contributing to several problems. No harm was identified or observed as a result of
administering ADRe.
Although several homes acknowledged delays in medication reviews, particularly for GP
prescriptions, only one (N10) of the 10 care home managers consulted pharmacists. Some
mentioned annual pharmacist reviews of MAR charts. Pharmacist interviewees explained that
pharmacists supplying medicines to care homes do not normally conduct medication reviews
unless specifically contracted to do so by the health board.
3. ADRe in practice
We identified several barriers to implementation and associated clinical gains, some more
surmountable than others. Barriers included time, integration with existing records and infor-
mation systems, complacency, prescribers’ attitudes, access to doctors, staff education and
turnover. Clinical gains from ADRe were facilitated by: allocation of one-to-one time, good
staff-resident relationships, unifying pertinent supporting information into a single document,
and making staff feel valued.
a) Barriers. Time. Time and conflicting work demands were the most frequently cited
barriers to regular use of ADRe. “The biggest barrier is time, but having said that, once you’ve
used the tool and you’ve used it regularly, it becomes second nature, so it’s not that time-con-
suming (N10). It’s like everything else really, slow at first and use it regularly and get quicker”
(N1). However, where attention to symptoms or de-prescribing made residents more comfort-
able, the residents were “more settled” (3.2, 4.3), less aggressive and with reduced incontinence
(10.2), less confused / sedated (10.1, 10.2, 10.4), warmer (2.3), pain-free (8.1, 9.2, 5.1, 5.2, 5.3),
less constipated (6.1) and accordingly easier and more pleasant to work with (Table 4). Time
taken to complete ADRe was extended by (unsuccessful) attempts to locate laboratory test
results and equipment. Prescribers’ time was also identified as a problem, and ADRe might
lead to more efficient use of this scarce resource (SU2).
Integration with existing records. Each care home had its own record system. ADRe uni-
fied existing data collection. As one informant said, more work is needed to “integrate into
routines, looking at whatever else they are monitoring with a view to keeping it manageable
and not distracting them from interaction with residents” (Su2).
Prescribers. Where prescribers engaged well with care home staff and residents, important
clinical gains were made (Table 4). In some instances, nurses needed to advocate for residents
to effect prescription changes. One nurse who successfully advocated for a reduction in anti-
psychotic prescribing said: “Pharmacists are keen to come on board, the consultants too. GPs
are a difficult group. (. . .) they always think they know best. (. . .) we all know that Joe Bloggs
doesn’t need the risperidone, but the GP thinks he does, so it’s getting round that sort of think-
ing. [. . . There is] resistance from the GPs because they might feel threatened, they think that
nurses shouldn’t be having any input–they know best” (N10). Sometimes, prescribers refused
to action problems identified: “ADRe picked up issues. Like I say, I spoke to the GP, they wer-
en’t forthcoming in helping: they shut me down” (N5). As a result, chest pain, dyspnoea and
insomnia were not addressed, despite requests for contact from residents.
Resignation. While some nurses effectively challenged prescribers, others had become
resigned to inertia: “Unlikely the medicines will be changed. I am sure they won’t be changed”
(N7). Some were disillusioned after repeated attempts to get medication reviewed: “You speak
to the receptionist that you want to speak with the GP with reference bla, bla, bla, you could be
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waiting two- three days. Then you get frustrated” (N5). Higher-level stakeholders acknowl-
edged that “a lot of people are on a lot of drugs that aren’t reviewed”I1.
Education and staff turnover. Nurses and care staff who participated soon became adept
in applying ADRe, and reported that ADRe was easy to use for 27 of 30 residents. Problems
with staff shortages and turnover militated against education initiatives, and managers in two
homes spoke of problems in ensuring that staff had sufficient information about medicines.
ADRe and supporting information attempted to fill this “education gap”, and interviewees
described it as an aide memoir that helped collect specific information in a systematic way.
b) Facilitators. Interpersonal relationships. ADRe depended on positive relationships
between residents, carers, nurses and prescribers. Both carers and residents appreciated the
one- to-one care, and its contribution to patient-centred care in which residents or families
could participate.
All information in one place. Offering prescribers a single document with problems
highlighted facilitated inter-professional communication, so that: “everyone is aware of what
issues are coming up with the patient, and the decisions can be made between all the healthcare
professionals” (P2). One nurse said: “They [doctors, pharmacists] don’t look at the assessments
and care plans and things that we do because it’s just mainly for the local health board and for
us to have, in order for us to handle the residents better” (N8). ADRe offered a quick and
accessible alternative to up to 20 detailed care plans, promoting clinical gains. This was a view
echoed by several respondents:
“All the information in one place allows you to focus on the person. (. . .) I did the profile
myself, (. . .), so I did the vital signs, wrote them all down and I looked through all this to see
any of the symptoms, ticked them off. (. . .) it was their agitation. I discussed with the GP then”
(N2).
“All the information on one piece of paper, (. . .), rather than going through separate pieces
in separate places. (. . .) If the doctor comes in and says “Have you done the observations?” it’s
all together in one place and you can give the details to the GP” (N9).
Recognising problems. Some nurses acknowledged that their familiarity with residents
might blind them to problems: “We get used to the person. We might omit some signs (. . .)
when you look over the profile it will ask you different questions that maybe you never thought
of: someone being on a different kind of tablet might give them tremor. You might see that but
might classify that as age. You might not actually put it as medication. So this is why the profile
is good” (N8). ADRe also crystallised nurses’ clinical suspicions that medicines were not opti-
mised, despite correct doses: “If we have got the evidence, they [doctors] are much more
inclined to take our word for it, listen to our point of view” (N3). However, ADRe was seen as
complex, and in the view of a few, over-complex. The comprehensiveness of the instrument
was both a weakness, in terms of being too difficult for some staff, and a strength, in that “[It]
puts little things together that may be missed” (N3). ADRe might allow insidious, subtle ADRs
to be detected and managed, and certain hard-to-diagnose conditions (hypothyroidism, perni-
cious anaemia) to be recognised and treated. When compared with easier tools, ADRe “covers
everything, but becomes lengthier. You won’t miss anything here, but administering this
would take more time and resources” (GP2).
Valuing staff. ADRe works by harnessing care staff’s familiarity with patients to inform
doctors of ongoing undesirable effects of medicines prescribed. The supporting information
provided with the ADRe Profile suggests which medicines might be responsible, and this guid-
ance can be used to support advocacy for review and revision: “I made notes on the profile, to
lead me in the right direction. Rather than just trying to put my opinion across, I had the evi-
dence in front of me: look this is her BP, her falls have increased–four times more. Having the
supporting information to say ‘it might be this medication, so can you come and review?’”
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(N6.2). “What it [ADRe] tends to do, is give value doesn’t it? The staff tend to feel the informa-
tion that they are gathering is of value. It improves morale. The care staff–the staff feel that
what they are doing is worthwhile and they are not just ticking forms, ticking boxes and just
getting filed away” (N3).
Changing priorities: Shifting the zeitgeist
The prevalence, severity and reversibility of problems identified by ADRe indicate that change
is both necessary and feasible. Respondents suggested that reducing the variation between
homes, services and prescribers will reduce ADRs and ADEs, and the burdens these place on
service users, staff and the NHS (Table C in S3 File). The service users were the group most dis-
satisfied with current practice, and the most enthusiastic advocates for ADRe, based on their
personal experiences and perceived need for change in mental health medication manage-
ment. Their perceptions are supported by the study pharmacist’s reviews (Table 3) and the
changes brought about by implementation of ADRe (Table 4).
Changes that would help protect patients from harm associated with ADRs/ADEs were
identified. These included shared access to essential information, improved staff education,
adequate staffing, communication with GPs, consultants and pharmacists, and prescription
reviews before repeats are issued (Table C in S3 File). ADRe made a contribution in several of
these areas, providing standardised patient data, informal, experiential education, a mecha-
nism for inter-professional communication and observations that feed into prescription
reviews.
All nurses and stakeholders agreed that the paper version of ADRe needs to be developed to
become compatible with digital information systems: “People won’t write it twice. (. . .) The
questions that you have here, they are good (. . .) the only problem is we already have a system
in place.” N8 (Table C in S3 File). Integrating ADRe with electronic patient records would
allow a number of tangible improvements, such as cross-population of the ADRe Profile from
other records (obviating the need for any duplication of recording), selective retrieval of rele-
vant information (e.g. positive responses only), examination of trends over time, and an online
link to interaction checkers. Developing an electronic version of ADRe appears a more useful
path for development than any effort to further shorten the instrument. The latter would risk
detracting from “the little things” that made ADRe comprehensive: “I don’t really know if it
could be condensed” (N3).
Discussion
Patient-centred medication review is essential. ADRe’s evolving evidence base indicates it can
be effective and acceptable in supporting reviews before repeat prescribing [22–24]. This study
indicates that ADRe brings several benefits: it relieves residents’ ADR burden of confusion,
sedation and EPS; alleviates falls, pain, and dyspnoea; optimises seizure control; and bridges
communication between residents, nurses and prescribers. However, to overcome the barriers
of time, education and staff turnover (only some homes), prescribers’ availability and compla-
cency, introducing ADRe into routine practice throughout the sector will need support from
regulators. Systematic, routine ADR monitoring needs to be integrated into existing care and
documentation. Where prescribers visited regularly, this was relatively straightforward; how-
ever, where doctors were uncontactable, it was difficult.
ADRs: An everyday problem in need of policy intervention
Meta-analyses identified little evidence for clinical gains from interventions to optimise pre-
scribing [31–33] or polypharmacy [34], or physical health, (except individualised exercise
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interventions) [35]. While many interventions [36–40] improve medication appropriateness,
links to patient outcomes are unclear [12, 31, 41, 42] ADRe is different [21]- it addresses the
“little” things affecting patients, as a preventive strategy, for example, by addressing dizziness,
balance and eyesight before falls happen (homes 1,2,6,7, Table 4) [43, 44].
ADRs and ADEs are common, though often unrecognised [8], and systematic checking
with ADRe increased recognition, reporting and actions [20, 24] Preventable problems were
almost universal, but often mundane, commonplace, un-recorded, and, consequently, over-
looked. ADRe helped to break the Inverse Interest Law: the commoner the problem, the less
the professional interest [45]. Without ADRe, clinically uninteresting, yet debilitating, condi-
tions, such as incontinence, confusion, xerostomia, hyper-salivation, and insomnia were often
under-investigated (all homes Table 4).
The differences in medical care available to residents in different homes, particularly access
to consultants [46], reflected the association between socio-economic deprivation and GP scar-
city [47], and the Inverse Care Law [48]. Without change in policy, homes in the poorest areas
will be the least able to adopt ADRe, because they cannot contact prescribers to address prob-
lems identified (homes 5 & 7, Table 5), and the most economically-deprived will continue to
be disproportionately represented amongst preventable unplanned hospital admissions [49].
Economics of ADRe
Many ADRs and ADEs are preventable, and there can be significant resource and cost implica-
tions for health systems in failing to tackle the problem. Patients experiencing avoidable
admissions and extended hospitalisation owing to avoidable ADR/ADE incur excess treatment
costs of between €2,851 (£2,463) and €9,015 (£7,787) per patient [50]. The application of sim-
ple and inexpensive interventions such as ADRe within routine care has the potential to mini-
mise preventable ADRs/ADEs. While the cost-effectiveness of any intervention must be
demonstrated based on robust evidence of clinical efficacy and effectiveness, the median time
required to complete ADRe was under 30 minutes, and in no cases exceeded an hour, suggest-
ing that staff costs will be minimal. While it is difficult to accurately estimate wages for care
home staff, a recently advertised post on www.carehome.co.uk, for a Care Home Clinical Lead
Registered Nurse paid £17.50 per hour. With salary on-costs (in the UK, typically for pension
contributions and employer national insurance contributions) of 15%, the cost per hour of
labour is roughly £20.00 per hour. A crude calculation suggests that, at the lower bound of the
cost of an ADR/ADE of about £2,400, one admission must be prevented for every 120 adminis-
trations of ADRe. Given that from 30 administrations, there were 17 referrrals, 5 interventions
for falls, 1 for chest pain, and 6 for dyspnoea, it is likely that this threshold was achieved. This
is a crude estimate based on the limited data available on both the costs of administering
ADRe and the costs of ADRs for people living in care homes. However, it usefully illustrates
that a low-tech intervention has the potential to provide benefit at health system level as well as
patient level. The two other interventions identified in a systematic review of trials of medi-
cines management interventions for people with dementia either depended on consultant
input (increasing costs) or focused on medication adherence [51].
From paper to electronic health records (EHRs)
Both time and EHRs were identified as barriers to implementation of ADRe, and these are
inter-related. EHRs can identify severe events [19], but have increased NHS workloads [52],
with electronic medicines optimisation a particular challenge [53]. Where clinical decision
support is poor, electronic prescribing increases errors [54], and ADRe’s supporting informa-
tion helps here. EHRs consume ~6 hours /day of responding doctors’ time and are associated
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with staff burnout in primary [55]and secondary care [56]. Electronic patient self-reporting of
adverse events is effective in oncology [57] but most residents were too poorly to self-report.
Although integration into EHRs overcomes some barriers (i.e. fitting into existing documenta-
tion, forcing responses to all items), it will not address others i.e. time, prescriber contact, staff
turnover and overwhelming systems (Table 5). Introducing ADRe against this background of
perceived stress and overwork is challenging. However, the initial time investment to complete
ADRe in face-to-face interviews is repaid when residents feel they have been heard and are less
confused and pain-free (Fig 2).
ADRe focuses multidisciplinary team communication
When medicines reviews are scheduled, giving pharmacists and prescribers a copy of ADRe
alongside the MAR chart links residents’ problems to the clinical goal of freedom from ADRs
(Fig 3) [58,59]. When reviewing medicines, pharmacists and doctors rarely have time to inter-
view patients about every possible adverse effect of all their medicines, many residents are
non-verbal, and the resident’s key carer is often off-duty, due to 12 hour shift patterns. For
example, laxatives are commonly prescribed, but ADRe was needed to tell the pharmacist that
the resident had diarrhoea, prompting adjusted prescribing (4 participants, Table 3). Some
~50% of ADRe’s signs and symptoms can be retrieved from patients’ notes, but this takes
1–1.5 hours [23, 24]. Medication reviews are labour-intensive [43], and under-resourced [60];
ADRe reduces overall costs by optimising pharmacists’ and prescribers’ time.
Fig 2. Energy and the ADRe profile. All things are difficult before they are easy, Thomas Fuller 1732. Fuller, T. (1732) Gnomologia: Adages and
Proverbs, Wise Sentences andWitty Sayings, Collected by Thomas Fuller, No. 560, p.21. London: Barker/Bettesworth and Hitch. Available at:
https://books.google.co.uk/books?id=3y8JAAAAQAAJ&printsec=frontcover#v=onepage&q&f=false.
https://doi.org/10.1371/journal.pone.0220885.g002
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Strengths and limitations
Linking problems with prescriptions via systematic nurse-led monitoring is a unique approach
to a large problem that is threatening to overwhelm care delivery [21, 22], including hospital
admissions [1–6]. Juxtaposition of prescriptions and problems clarified mechanisms for clini-
cal improvements. Without this detail, the complexities of the cases would have been over-
looked, problems would have remained unattended, and residents left in pain or falling.
However, some ADRe items were omitted, particularly time-consuming vital signs, or
unaddressed.
We acknowledge that this study is limited by selection bias, selection by prescriptions rather
than diagnostic codes, size, and self-reporting in interviews. Although we focussed on objec-
tive clinical findings, no researchers can discount entrapment by prior expectation [61] or sub-
conscious outcome reporting bias favouring benefits and discounting harm caused by the
intervention. There is a risk that researcher expectancy bias will lead the study to exaggerate
ADRe’s ability to detect problems and underplay implementation difficulties. However, we
sought to ensure that problems identified were real by observation and using care homes’ own
logs as evidence of adverse reactions or risks identified, and getting these verified by an inde-
pendent pharmacist recruited to the team. We assessed ADRe’s “usability” from observations
and staff reports in interviews, which were coded by multiple team members who were well
aware that it would be counterproductive to exaggerate acceptability. Moreover, reporting was
unaffected by the more pervasive and serious “reciprocation” or commercial interest biases
[62].
Concerns over potential volunteer bias in care home selection emerged when 3 homes
withdrew, citing difficulties in maintaining effective service delivery affecting their ability to
participate: others note that only interested, “good” homes, with open-door policies welcome
researchers [24, 63]. The observation that some of our homes were in economically deprived
Fig 3. Integrating ADRe into multidisciplinary teams.
https://doi.org/10.1371/journal.pone.0220885.g003
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areas, with poor GP contact [48], increases the transferability of the findings, but we acknowl-
edge generalisation of findings is based on logical, rather than statistical, inference [21] and
can best be confirmed by replication studies of additional settings [64]. However, these find-
ings show how residents can be helped, without sedation or exposure to risk from prescribed
medicines: the challenges are to persuade everyone to emulate the best, to show that ADRe is
easy to use and, with experience, the initial effort is more than repaid by clinical gain (Fig 2).
None of the 34 methods for ADR causality assessment is universally accepted [65] or easy
to apply in practice [66]. This study identified putative ADRs, which were sometimes con-
firmed by de-prescribing. It was beyond the study’s scope to identify errors or to systematically
de-challenge and re-challenge participants with suspected medicines to determine which, if
any, of the prescribed medicines was responsible in each case. Re-challenge is rarely practical,
and formal assessments of ADR causality cannot confer certainty, prove a connection or quan-
tify a contribution [67]; they rarely achieve consensus [68].
The study’s limited duration, resources, and size precluded detailed follow up of all partici-
pants, and uncommon events. The 30 detailed cases indicated data saturation, and triangula-
tion of stakeholders’ views with cases (Table 5) demonstrated how ADRe can and should
work.
Implications for practice: The case for change
ADRe is needed to minimise pain, dyspnoea, sedation, confusion, insomnia, EPS, falls, incon-
tinence, and aggression. The problems addressed here permeate health and social care services
[2, 8, 12]. The change in thinking to reflectively link problems with known ADRs is a barrier
to be negotiated, but the pervasiveness of unmonitored harm and entrapment by prior expec-
tation are profound challenges [2, 8, 12, 69]. Adjusting healthcare systems to check systemati-
cally for iatrogenic harm may be difficult until the benefits of minimising medicines-related
harm are understood, the process is normalised [70] and gatekeepers accept that patients need
strategies to communicate their signs, symptoms and concerns [71].
Demographic and prescribing changes are increasing the need for a comprehensive, sys-
tematic multi-professional approach to medicines optimisation. In the UK in 2008–11, 49%
(of 7359) of people aged 65 and over took more than four medicines, a fourfold increase since
1991–5 [72], whilst emergency admissions for ADRs rose [73]. Life expectancy is no longer ris-
ing [74].
The WHO asks health ministries to programme changes in professionals’ behaviour, sys-
tems and practices of medication management to reduce ADRs, polypharmacy and miscom-
munication [75, 76]. Workforce constraints suggest this may be best achieved by extending
and expanding nurses’ roles, building on nurses’ knowledge and communication skills. ADRe
can do this and address long-standing problems. Presenting evidence to gatekeepers is insuffi-
cient [77] change is mediated through social networks, power structures, and professional poli-
tics. The challenge is to persuade policy makers that a person-centred [78], clinically and cost-
effective tool, such as ADRe, [24] deserves support.
Note: In the Welsh language “Adre” means homewards. We hope the ADRe profile will
bring a sense of greater security for those prescribed mental health medicines.
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